Home Newsfeeds Harley-Davidson CEO Says The Company Has Secured Supply For Its EV Bikes For The ‘Next Few Years’

News

Harley-Davidson CEO Says The Company Has Secured Supply For Its EV Bikes For The ‘Next Few Years’

-CNBC Interview

byBenzinga Newsdesk

September 27, 2022

1 minute read

-CNBC Interview

Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity Of In Ovarian And Colorectal Cancer Models At The AACR Annual Meeting

By Happy Mohamed

April 19, 8:46 AM

- Highly significant (p<0.0001) reduction in tumor volume in ovarian cancer model when using HER3-ARC conjugated to either Actinium-225 or Lutetium-177 compared to bevacizumab (Avastin) - HER3 is

ATNM

Reported Earlier, Panbela Announces Poster Presentation At Immunology Of Diabetes Society Meeting: Evaluating The Potential Of CPP-1X In Recent Onset Type 1 Diabetes

By Happy Mohamed

June 1, 9:47 AM

Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation

PBLA

CONMED Sees FY23 EPS $3.30-$3.50 Vs $3.20-$3.45 Previous Estimate; FY23 Revenue $1.205B-$1.250B Vs $1.17B-$1.22B Est.

By Happy Mohamed

April 26, 4:21 PM

2023 Outlook Based on the first quarter results, the Company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.205 billion and $1.250 2023 Outlook

CNMD

Truist Securities Maintains Hold on International Paper, Raises Price Target to $38

By Benzinga Newsdesk

February 1, 9:08 AM

Truist Securities analyst Michael Roxland maintains International Paper (NYSE:IP) with a Hold and raises the price target from $30 to $38.

Harley-Davidson CEO Says The Company Has Secured Supply For Its EV Bikes For The ‘Next Few Years’

Related Posts

Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity Of In Ovarian And Colorectal Cancer Models At The AACR Annual Meeting

Reported Earlier, Panbela Announces Poster Presentation At Immunology Of Diabetes Society Meeting: Evaluating The Potential Of CPP-1X In Recent Onset Type 1 Diabetes

CONMED Sees FY23 EPS $3.30-$3.50 Vs $3.20-$3.45 Previous Estimate; FY23 Revenue $1.205B-$1.250B Vs $1.17B-$1.22B Est.

Truist Securities Maintains Hold on International Paper, Raises Price Target to $38